The Identification, Review and Synthesis of Health State Utility Values from the Literature
Author
Abstract
Suggested Citation
DOI: 10.1007/s40273-017-0547-8
Download full text from publisher
As the access to this document is restricted, you may want to search for a different version of it.
References listed on IDEAS
- Donna Rowen & John Brazier & Roberta Ara & Ismail Azzabi Zouraq, 2017. "The Role of Condition-Specific Preference-Based Measures in Health Technology Assessment," PharmacoEconomics, Springer, vol. 35(1), pages 33-41, December.
- John Brazier & Roberta Ara & Donna Rowen & Helene Chevrou-Severac, 2017. "A Review of Generic Preference-Based Measures for Use in Cost-Effectiveness Models," PharmacoEconomics, Springer, vol. 35(1), pages 21-31, December.
- Roberta Ara & Donna Rowen & Clara Mukuria, 2017. "The Use of Mapping to Estimate Health State Utility Values," PharmacoEconomics, Springer, vol. 35(1), pages 57-66, December.
Citations
Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
Cited by:
- Lin Li & J L (Hans) Severens & Olena Mandrik, 2019. "Disutility associated with cancer screening programs: A systematic review," PLOS ONE, Public Library of Science, vol. 14(7), pages 1-17, July.
- Feng Xie & Michael Zoratti & Kelvin Chan & Don Husereau & Murray Krahn & Oren Levine & Tammy Clifford & Holger Schunemann & Gordon Guyatt, 2019. "Toward a Centralized, Systematic Approach to the Identification, Appraisal, and Use of Health State Utility Values for Reimbursement Decision Making: Introducing the Health Utility Book (HUB)," Medical Decision Making, , vol. 39(4), pages 371-379, May.
- Roberta Ara & Donna Rowen & Clara Mukuria, 2017. "The Use of Mapping to Estimate Health State Utility Values," PharmacoEconomics, Springer, vol. 35(1), pages 57-66, December.
Most related items
These are the items that most often cite the same works as this one and are cited by the same works as this one.- Roberta Ara & John Brazier & Tracey Young, 2017. "Recommended Methods for the Collection of Health State Utility Value Evidence in Clinical Studies," PharmacoEconomics, Springer, vol. 35(1), pages 67-75, December.
- Richard Huan Xu & Eliza Lai-yi Wong & Nan Luo & Richard Norman & Jens Lehmann & Bernhard Holzner & Madeleine T. King & Georg Kemmler, 2024. "The EORTC QLU-C10D: the Hong Kong valuation study," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 25(5), pages 889-901, July.
- Nathan S. McClure & Mike Paulden & Arto Ohinmaa & Jeffrey A. Johnson, 2021. "Modifying the quality-adjusted life year calculation to account for meaningful change in health-related quality of life: insights from a pragmatic clinical trial," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 22(9), pages 1441-1451, December.
- Roberta Ara & John Brazier & Ismail Azzabi Zouraq, 2017. "The Use of Health State Utility Values in Decision Models," PharmacoEconomics, Springer, vol. 35(1), pages 77-88, December.
- Paul Schneider & Nancy Devlin & Ben van Hout & John Brazier, 2024. "Exploring health preference heterogeneity in the UK: Using the online elicitation of personal utility functions approach to construct EQ‐5D‐5L value functions on societal, group and individual level," Health Economics, John Wiley & Sons, Ltd., vol. 33(5), pages 894-910, May.
- Michela Meregaglia & Elena Nicod & Michael Drummond, 2023. "The estimation of health state utility values in rare diseases: do the approaches in submissions for NICE technology appraisals reflect the existing literature? A scoping review," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 24(7), pages 1151-1216, September.
- Madeleine T. King & Rosalie Viney & A. Simon Pickard & Donna Rowen & Neil K. Aaronson & John E. Brazier & David Cella & Daniel S. J. Costa & Peter M. Fayers & Georg Kemmler & Helen McTaggart-Cowen & R, 2018. "Australian Utility Weights for the EORTC QLU-C10D, a Multi-Attribute Utility Instrument Derived from the Cancer-Specific Quality of Life Questionnaire, EORTC QLQ-C30," PharmacoEconomics, Springer, vol. 36(2), pages 225-238, February.
- Fan Yang & Carlos K. H. Wong & Nan Luo & James Piercy & Rebecca Moon & James Jackson, 2019. "Mapping the kidney disease quality of life 36-item short form survey (KDQOL-36) to the EQ-5D-3L and the EQ-5D-5L in patients undergoing dialysis," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 20(8), pages 1195-1206, November.
- Samer A. Kharroubi & Donna Rowen, 2019. "Valuation of preference-based measures: can existing preference data be used to select a smaller sample of health states?," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 20(2), pages 245-255, March.
- Samer A. Kharroubi & Yara Beyh & Marwa Diab El Harake & Dalia Dawoud & Donna Rowen & John Brazier, 2020. "Examining the Feasibility and Acceptability of Valuing the Arabic Version of SF-6D in a Lebanese Population," IJERPH, MDPI, vol. 17(3), pages 1-15, February.
- Aileen R. Neilson & Gareth T. Jones & Gary J. Macfarlane & Ejaz MI Pathan & Paul McNamee, 2022. "Generating EQ-5D-5L health utility scores from BASDAI and BASFI: a mapping study in patients with axial spondyloarthritis using longitudinal UK registry data," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 23(8), pages 1357-1369, November.
- Samer A. Kharroubi & Yara Beyh, 2021. "Bayesian modeling of health state preferences: could borrowing strength from existing countries’ valuations produce better estimates," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 22(5), pages 773-788, July.
- Satar Rezaei & Abraha Woldemichael & Sina Ahmadi & Amjad Mohamadi Bolbanabad & Farman Zahir Abdullah & Bakhtiar Piroozi, 2021. "Comparing the properties of the EQ‐5D‐5L and EQ‐5D‐3L in general population in Iran," International Journal of Health Planning and Management, Wiley Blackwell, vol. 36(5), pages 1613-1625, September.
- Jonathan Karnon, 2017. "Heath State Utility Values for Cost-Effectiveness Models," PharmacoEconomics, Springer, vol. 35(1), pages 1-3, December.
- Donna Rowen & John Brazier & Roberta Ara & Ismail Azzabi Zouraq, 2017. "The Role of Condition-Specific Preference-Based Measures in Health Technology Assessment," PharmacoEconomics, Springer, vol. 35(1), pages 33-41, December.
- Pickles, Kristen & Lancsar, Emily & Seymour, Janelle & Parkin, David & Donaldson, Cam & Carter, Stacy M., 2019. "Accounts from developers of generic health state utility instruments explain why they produce different QALYs: A qualitative study," Social Science & Medicine, Elsevier, vol. 240(C).
- Koonal K. Shah & Bryan Bennett & Andrew Lenny & Louise Longworth & John E. Brazier & Mark Oppe & A. Simon Pickard & James W. Shaw, 2021. "Adapting preference-based utility measures to capture the impact of cancer treatment-related symptoms," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 22(8), pages 1301-1309, November.
- Richard Norman & Rebecca Mercieca‐Bebber & Donna Rowen & John E. Brazier & David Cella & A. Simon Pickard & Deborah J. Street & Rosalie Viney & Dennis Revicki & Madeleine T. King & On behalf of the Eu, 2019. "U.K. utility weights for the EORTC QLU‐C10D," Health Economics, John Wiley & Sons, Ltd., vol. 28(12), pages 1385-1401, December.
- Ângela Jornada Ben & Johanna M. Dongen & Aureliano Paolo Finch & Mohamed El Alili & Judith E. Bosmans, 2023. "To what extent does the use of crosswalks instead of EQ-5D value sets impact reimbursement decisions?: a simulation study," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 24(8), pages 1253-1270, November.
Corrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:pharme:v:35:y:2017:i:1:d:10.1007_s40273-017-0547-8. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com .
Please note that corrections may take a couple of weeks to filter through the various RePEc services.